Skip to main content
Published Online:https://doi.org/10.3928/23258160-20130715-01Cited by:1

Abstract

This editorial discusses the significance of the first reported case series of real-world use of ocriplasmin for treating symptomatic vitreomacular adhesion and addresses the importance of case selection in improving treatment results.

We use cookies on this site to enhance your user experience. For a complete overview of all the cookies used, please see our privacy policy.

×